Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: Studies with chimeric receptors

被引:46
作者
Ellis, J
Seidenberg, M
机构
[1] Penn State Univ, Coll Med, Dept Psychiat, Hershey, PA USA
[2] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA USA
关键词
D O I
10.1124/mol.58.6.1451
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A series of ligands that allosterically modulate the binding of classical ligands to muscarinic receptors was evaluated at wildtype and chimeric receptors. All of the ligands studied had highest affinity toward the M-2 subtype and lowest affinity toward the M-5 subtype. The chimeric receptors were mostly M-5 sequence; the amount of M-2 sequence ranged from about 6 to just under 30%. Alcuronium and TMB-8 had much higher affinity for the chimeric receptor that included the M-2 second outer loop of the receptor plus flanking regions of TM4 and TM5 than for any of the other chimeric receptors (the affinities of which remained similar to that of the M-5 subtype). However, this chimera retained the negative cooperativity between alcuronium and the classical antagonist N-methylscopolamine that is characteristic of M-5 (these ligands are positively cooperative at M-2). Verapamil, tetrahydroaminoacridine, and d-tubocurarine were also sensitive to that chimeric substitution, although verapamil and tetrahydroaminoacridine had even higher affinity for a chimera with M-2 sequence in TM7. None of these ligands shared gallamine's sensitivity to a region of the third outer loop, but studies in which obidoxime reversed the allosteric effects of gallamine and other ligands suggested that they nevertheless compete for a common site. In summary, although the present data are consistent with previous studies that have suggested that allosteric ligands bind to the outermost regions of muscarinic receptors, it appears that different allosteric ligands may derive subtype selectivity from different regions of the receptor.
引用
收藏
页码:1451 / 1460
页数:10
相关论文
共 36 条
[1]   ALLOSTERIC REGULATION OF G-PROTEIN-LINKED RECEPTORS [J].
BIRDSALL, NJM ;
COHEN, F ;
LAZARENO, S ;
MATSUI, H .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (01) :108-111
[2]   EFFECTS OF IONS ON THE BINDING OF AGONISTS AND ANTAGONISTS TO MUSCARINIC RECEPTORS [J].
BIRDSALL, NJM ;
BURGEN, ASV ;
HULME, EC ;
WELLS, JW .
BRITISH JOURNAL OF PHARMACOLOGY, 1979, 67 (03) :371-377
[3]   Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes [J].
Birdsall, NJM ;
Farries, T ;
Gharagozloo, P ;
Kobayashi, S ;
Kuonen, D ;
Lazareno, S ;
Popham, A ;
Sugimoto, M .
LIFE SCIENCES, 1997, 60 (13-14) :1047-1052
[4]  
BRUNS RF, 1990, MOL PHARMACOL, V38, P939
[5]  
Caulfield MP, 1998, PHARMACOL REV, V50, P279
[6]   Allosteric interactions at muscarinic cholinoceptors [J].
Christopoulos, A ;
Lanzafame, A ;
Mitchelson, F .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1998, 25 (3-4) :185-194
[7]  
CURTIS CAM, 1989, J BIOL CHEM, V264, P489
[9]  
ELLIOTT ED, 1991, KAN JL PUB POLY, V1, P5
[10]   Site-directed mutagenesis implicates a threonine residue in TM6 in the subtype selectivities of UH-AH 37 and pirenzepine at muscarinic receptors [J].
Ellis, J ;
Seidenberg, M .
PHARMACOLOGY, 2000, 61 (02) :62-69